Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

September 29, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions

Gastric Cancer

Interventions

DRUG

HLX22

IV Q3W D1

DRUG

Placebo

IV Q3W D1

DRUG

Trastuzumab

IV Q3W D1

DRUG

Oxaliplatin

IV Q3W D1

DRUG

Capecitabine

PO Q3W D1-D14

Trial Locations (1)

Shanghai East Hospital, Shanghai

All Listed Sponsors

lead

Shanghai Henlius Biotech

INDUSTRY